Bulletin
Investor Alert

New York Markets Open in:

Biogen Inc.

NAS: BIIB

GO
/marketstate/country/us

Before the Bell

 --Quotes are delayed by 20 min

Dec 13, 2019, 5:15 a.m.

/zigman2/quotes/201531540/composite

$

297.60

Change

+3.75 +1.28%

Volume

Volume 939

Quotes are delayed by 20 min

/zigman2/quotes/201531540/composite

Previous close

$ 293.85

$ 293.85

Change

+1.62 +0.55%

Day low

Day high

$290.93

$296.17

Open

52 week low

52 week high

$215.78

$344.00

Open

Company Description

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment o...

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Valuation

P/E Current

13.54

P/E Ratio (with extraordinary items)

9.98

P/E Ratio (without extraordinary items)

13.94

Price to Sales Ratio

5.13

Price to Book Ratio

4.55

Price to Cash Flow Ratio

9.98

Enterprise Value to EBITDA

9.73

Enterprise Value to Sales

4.49

Total Debt to Enterprise Value

0.09

Efficiency

Revenue/Employee

1,545,218.00

Income Per Employee

568,038.00

Receivables Turnover

5.02

Total Asset Turnover

0.49

Liquidity

Current Ratio

2.32

Quick Ratio

2.04

Cash Ratio

1.07

Profitability

Gross Margin

81.77

Operating Margin

42.83

Pretax Margin

48.95

Net Margin

36.76

Return on Assets

18.11

Return on Equity

34.54

Return on Total Capital

27.53

Return on Invested Capital

23.62

Capital Structure

Total Debt to Total Equity

45.53

Total Debt to Total Capital

31.28

Total Debt to Total Assets

23.47

Long-Term Debt to Equity

45.53

Long-Term Debt to Total Capital

31.28

Officers and Executives

Name Age Officer Since Title
Mr. Michel Vounatsos 55 2016 Chief Executive Officer & Director
Mr. Jeffrey D. Capello 53 2017 Chief Financial Officer & Executive Vice President
Dr. Alfred W. Sandrock 61 1998 Chief Medical Officer & EVP-Research & Development
Mr. Mark Hernon - 2017 Chief Information Officer & Senior Vice President
Dr. Alphonse Galdes - 1995 SVP-Asset Development & Portfolio Management

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
12/03/2019 Robin C. Kramer
VP, Chief Accounting Officer
25   Derivative/Non-derivative trans. at $290.7 per share. 7,267
12/03/2019 Robin C. Kramer
VP, Chief Accounting Officer
84   Derivative/Non-derivative trans. at $0 per share. 0
12/02/2019 Brian S. Posner
Director
1,055   Disposition at $292.35 per share. 308,429
12/01/2019 Chirfi Guindo
EVP Glob. Prod Strat and Comm
160   Derivative/Non-derivative trans. at $299.81 per share. 47,969
12/01/2019 Chirfi Guindo
EVP Glob. Prod Strat and Comm
231   Derivative/Non-derivative trans. at $299.81 per share. 69,256
12/01/2019 Chirfi Guindo
EVP Glob. Prod Strat and Comm
543   Derivative/Non-derivative trans. at $0 per share. 0
08/01/2019 Ginger Gregory
EVP, Human Resources
80   Derivative/Non-derivative trans. at $243.06 per share. 19,444
08/01/2019 Ginger Gregory
EVP, Human Resources
128   Derivative/Non-derivative trans. at $243.06 per share. 31,111
08/01/2019 Ginger Gregory
EVP, Human Resources
179   Derivative/Non-derivative trans. at $0 per share. 0
07/02/2019 Daniel Karp
EVP, Corporate Development
58   Derivative/Non-derivative trans. at $236.37 per share. 13,709
07/02/2019 Daniel Karp
EVP, Corporate Development
196   Derivative/Non-derivative trans. at $0 per share. 0
06/19/2019 Stelios B. Papadopoulos
Director
1,905   Award at $0 per share. 0
06/19/2019 Caroline D. Dorsa
Director
1,155   Award at $0 per share. 0
06/19/2019 Robert W. Pangia
Director
1,155   Award at $0 per share. 0
06/19/2019 Eric K. Rowinsky
Director
1,155   Award at $0 per share. 0
06/19/2019 Lynn Schenk
Director
1,155   Award at $0 per share. 0
06/19/2019 Nancy L. Leaming
Director
1,155   Award at $0 per share. 0
06/19/2019 Alexander John Denner
Director
1,155   Award at $0 per share. 0
06/19/2019 Richard Charles Mulligan
Director
1,155   Award at $0 per share. 0
06/19/2019 Brian S. Posner
Director
1,155   Award at $0 per share. 0
06/19/2019 Stephen A. Sherwin
Director
1,155   Award at $0 per share. 0
06/19/2019 William A. Hawkins
Director
1,155   Award at $0 per share. 0
06/19/2019 Jesus B. Mantas
Director
1,155   Award at $0 per share. 0
06/01/2019 Michael D. Ehlers
EVP, Research and Development
500   Derivative/Non-derivative trans. at $219.29 per share. 109,645
06/01/2019 Michael D. Ehlers
EVP, Research and Development
460   Derivative/Non-derivative trans. at $219.29 per share. 100,873
06/01/2019 Michael D. Ehlers
EVP, Research and Development
1,126   Derivative/Non-derivative trans. at $0 per share. 0
05/02/2019 Michel Vounatsos
Chief Executive Officer; Director
658   Derivative/Non-derivative trans. at $230.52 per share. 151,682
05/02/2019 Michel Vounatsos
Chief Executive Officer; Director
1,480   Derivative/Non-derivative trans. at $0 per share. 0
05/01/2019 Michel Vounatsos
Chief Executive Officer; Director
4,351   Acquisition at $231.48 per share. 1,007,169
03/18/2019 Robert W. Pangia
Director
6,114   Disposition at $328.55 per share. 2,008,754
03/18/2019 Robert W. Pangia
Director
6,114   Derivative/Non-derivative trans. at $52.22 per share. 319,273
/news/latest/company/us/biib

MarketWatch News on BIIB

  1. Cassava stock is up on Alzheimer's data

    10:58 a.m. Dec. 6, 2019

    - Jaimy Lee

  2. Money Is Moving Back Into Surging Biotech Funds

    10:22 a.m. Dec. 6, 2019

    - Josh Nathan-Kazis

  3. Biogen Is Up After an Alzheimer-Drug Presentation

    4:06 p.m. Dec. 5, 2019

    - Josh Nathan-Kazis

  4. The Dow Goes Negative Despite a Glimmer of Hope on Trade

    12:56 p.m. Dec. 5, 2019

    - Ben Walsh

  5. Wild Moves In Biotech Amid Deluge of Trial Data

    12:46 p.m. Dec. 5, 2019

    - Josh Nathan-Kazis

  6. Biogen shares rise on Alzheimer's candidate data

    12:22 p.m. Dec. 5, 2019

    - Jaimy Lee

  7. Biogen stock down 3.3% after resuming trade following halt

    11:36 a.m. Dec. 5, 2019

    - Ciara Linnane

  8. Biogen stock halted for presentation on Alzheimer's treatment

    11:13 a.m. Dec. 5, 2019

    - Ciara Linnane

  9. Anavex shares rise in advance of Alzheimer's meeting

    10:13 a.m. Dec. 4, 2019

    - Jaimy Lee

  10. Biogen’s Alzheimer’s Drug Won’t Get Approved, Analyst Says

    10:58 a.m. Dec. 2, 2019

    - Josh Nathan-Kazis

  11. The Seasonal Fitness Fit

    7:13 p.m. Nov. 29, 2019

    - Evie Liu

  12. The 3 Worst-Performing Health Care Stocks of 2019 So Far

    7:00 a.m. Nov. 28, 2019

    - Josh Nathan-Kazis

  13. Biotech Stock Funds Continue to See Money Exit

    8:28 a.m. Nov. 22, 2019

    - Josh Nathan-Kazis

  14. Loading more headlines...
/news/nonmarketwatch/company/us/biib

Other News on BIIB

  1. House passes drug pricing bill, Senate unlikely to support

    4:30 p.m. Dec. 12, 2019

    - Seeking Alpha

  2. Major Biotechs See a Rising Tide in Short Interest

    8:14 a.m. Dec. 11, 2019

    - 247WallSt.com

  3. Stocks To Watch: Netflix, Cisco And Chewy On The Marquee

    9:03 a.m. Dec. 7, 2019

    - Seeking Alpha

  4. Best Large-Cap Stocks To Buy Now

    8:01 a.m. Dec. 6, 2019

    - Seeking Alpha

  5. Biogen Details Case for Controversial Alzheimer’s Drug

    5:09 p.m. Dec. 5, 2019

    - Joseph Walker

  6. 5 Top Stock Trades for Friday: RH, DG, KR, BIIB

    4:17 p.m. Dec. 5, 2019

    - InvestorPlace.com

  7. IBB Is Positioned For Outperformance

    3:43 p.m. Dec. 5, 2019

    - Seeking Alpha

  8. Acadia Presents More Positive Data, Outlook Grows Stronger

    2:05 p.m. Dec. 5, 2019

    - Seeking Alpha

  9. Safety and Biotech Investing Don’t Mix

    12:58 p.m. Dec. 5, 2019

    - Charley Grant

  10. Biogen's aducanumab showed mixed results in Alzheimer's studies

    11:41 a.m. Dec. 5, 2019

    - Seeking Alpha

  11. Mike Khouw Highlights Unusual Options Activity In Biogen

    10:18 a.m. Dec. 5, 2019

    - benzinga.com

  12. Loading more headlines...

At a Glance

Biogen, Inc.

225 Binney Street

Cambridge, Massachusetts 02142

Phone

1 6176792000

Industry

Biotechnology

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2019

Revenue

$12.05B

Net Income

$4.43B

2018 Sales Growth

9.7%

Employees

7,800

/news/pressrelease/company/us/biib

Press Releases on BIIB

  1. Loading more headlines...
Trending Tickers
  • /quotes/zigman/17636479/composite VUZI+15.60%
  • /quotes/zigman/237947/composite JCP-5.83%
  • /quotes/zigman/59392505/composite NUGT-2.93%
  • /quotes/zigman/59386294/composite JNUG-5.94%
  • /quotes/zigman/65801738/composite TLT+1.11%
X
Powered by StockTwits
Link to MarketWatch's Slice.